Suppr超能文献

雷帕霉素、FK 506和环孢素对大鼠抗体产生、淋巴细胞群体及免疫球蛋白同种型转换的比较作用

Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat.

作者信息

Thomson A W, Propper D J, Woo J, Whiting P H, Milton J I, Macleod A M

机构信息

Department of Pathology, University of Aberdeen, UK.

出版信息

Immunopharmacol Immunotoxicol. 1993 Aug;15(4):355-69. doi: 10.3109/08923979309035233.

Abstract

The immunosuppressive activity and comparative efficacy of rapamycin (RAPA), FK 506 and cyclosporine A (CsA) were investigated in rats following immunization with either xenogeneic sheep red blood cells (SRBC) or allogeneic blood transfusion. RAPA formulated in a polyethylene glycol vehicle, and at a dose of 1.5 mg.kg-1 i.p., was relatively ineffective when compared with FK 506 (1 mg.kg-1) or CsA (15 mg.kg-1) in suppressing antibody production to SRBC. Like FK 506 and CsA however, RAPA proved highly effective in suppressing both the B lymphocytosis and the increase in circulating major histocompatibility complex class II+ cells observed following immunization. All three immunosuppressants caused thymic medullary atrophy, with evidence of epithelial cell damage and increased macrophage phagocytic activity. Administered i.m. (3 mg.kg-1 in olive oil), RAPA was also highly effective in suppressing 1 degree alloantibody responses to MHC class I antigens following blood transfusion. Unlike FK 506 and CsA however, a short (14-day) course of RAPA following 1 degree immunization (transfusion) did no suppress 2 degree alloantibody responses elicited 6 weeks later. Moreover, RAPA did not prevent immunoglobulin isotype switching as observed with FK 506 and CsA. This may reflect the distinct mechanisms of action of RAPA and the latter two agents on T-cell activation/proliferation. Further comparative and combination studies of RAPA with in particular, CsA, are required to further explore to potential of RAPA as an immunotherapeutic agent.

摘要

在用异种羊红细胞(SRBC)免疫或同种异体输血后的大鼠中,研究了雷帕霉素(RAPA)、FK 506和环孢素A(CsA)的免疫抑制活性及比较疗效。与FK 506(1mg.kg-1)或CsA(15mg.kg-1)相比,以聚乙二醇载体配制、剂量为1.5mg.kg-1腹腔注射的RAPA在抑制针对SRBC的抗体产生方面相对无效。然而,与FK 506和CsA一样,RAPA在抑制免疫后观察到的B淋巴细胞增多和循环中主要组织相容性复合体II类+细胞增加方面被证明是高度有效的。所有三种免疫抑制剂均导致胸腺髓质萎缩,有上皮细胞损伤和巨噬细胞吞噬活性增加的证据。肌肉注射(在橄榄油中为3mg.kg-1)时,RAPA在抑制输血后对MHC I类抗原的一级同种异体抗体反应方面也非常有效。然而,与FK 506和CsA不同,一级免疫(输血)后短期(14天)的RAPA疗程并不能抑制6周后引发的二级同种异体抗体反应。此外,与FK 506和CsA不同,RAPA不能阻止免疫球蛋白同种型转换。这可能反映了RAPA与后两种药物在T细胞活化/增殖方面不同的作用机制。需要对RAPA特别是与CsA进行进一步的比较和联合研究,以进一步探索RAPA作为免疫治疗药物的潜力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验